drugset
drugset / Trial / NCT00335335

Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the Heart

NCT00335335 ↗

Phase 3 Terminated 89 enrolled GE Healthcare
Non-randomizedSingle-groupOpen-labelDiagnostic

Summary

CT (computed tomography) angiography (CTA) is an examination similar to a CAT scan that uses x-rays and a contrast medium (also called dye) to visualize blood flow in arteries and veins throughout the body. VISIPAQUE™ will be given through a vein in the arm before having the CTA scan of the heart arteries. The pictures it produces of the heart and its blood vessels will be reviewed and compared to those obtained during the catheter-based coronary angiography to see if the CTA shows the same blockages.

Timeline

Start
2006-05
Primary completion
2006-12-02
Completion
2006-12-02

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision due to low subject recrcuitment”

Drugs

EvaluationDrugModalityDoseRoute
Subject Iodixanol Diagnostic / imaging agent 80 ml Intravenous

Indications

coronary artery disorder